UroPartners is the only community-based urology group in the Chicagoland area to have access to a new, breakthrough treatment for certain men with advanced prostate cancer who have limited treatment options. PROVENGE, an FDA-approved vaccine, is designed to work differently than hormone therapy or chemotherapy. As an autologous cellular immunotherapy, this treatment uses cells from a patient's own immune system to identify and attack prostate cancer cells.
Treatment with PROVENGE includes three doses given approximately two weeks apart. After three infusions, treatment with PROVENGE is complete. Potential reactions include fever and flu-like symptoms, but the procedure is generally well-tolerated.
For more information about this promising new treatment, talk with a UroPartners physician.